Clinical Trial Update: The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating Tusamitamab Ravtansine (IBI126) with Sintilimab, with or without platinum-based chemotherapy and pemetrexed, in CEACAM5-positive adva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pemetrexed (pemetrexed)
• Platinum-based chemotherapy (platinum-based chemotherapy)
• Sintilimab (sintilimab)
• Tusamitam Ravtansine (IBI126) (tusamitamab ravtansine)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Non-squamous Non-small-cell Lung Cancer | Phase 2 | Status: TERMINATED